TY - JOUR
T1 - Infliximab for reversible dementia in acute onset of neuro-Behçet's disease
T2 - A case report and cytokine analysis
AU - Imabayashi, Keisuke
AU - Ayano, Masahiro
AU - Higashioka, Kazuhiko
AU - Yokoyama, Kana
AU - Yamamoto, Ken
AU - Takayama, Koji
AU - Mitoma, Hiroki
AU - Kimoto, Yasutaka
AU - Akahoshi, Mitsuteru
AU - Arinobu, Yojiro
AU - Akashi, Koichi
AU - Horiuchi, Takahiko
AU - Niiro, Hiroaki
N1 - Funding Information:
The authors would like to thank Enago (www.enago.jp) for the English language review.
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/8/15
Y1 - 2021/8/15
N2 - We describe a 49-year-old female patient with neuro-Behçet's disease (NBD) with acute onset of fever and symptoms of dementia. High-dose glucocorticoid was partially effective for cognitive impairment, and infliximab, an anti-TNF-α antibody, gradually improved the symptoms. An analysis of cytokines showed that IP-10 in the cerebrospinal fluid was higher than that in the peripheral blood, and both decreased after treatment. This is the first known case of NBD wherein the patient with acute onset of dementia responded to a treatment with infliximab. In glucocorticoid-resistant patients, it is important to consider the introduction of infliximab to prevent irreversible brain dysfunction.
AB - We describe a 49-year-old female patient with neuro-Behçet's disease (NBD) with acute onset of fever and symptoms of dementia. High-dose glucocorticoid was partially effective for cognitive impairment, and infliximab, an anti-TNF-α antibody, gradually improved the symptoms. An analysis of cytokines showed that IP-10 in the cerebrospinal fluid was higher than that in the peripheral blood, and both decreased after treatment. This is the first known case of NBD wherein the patient with acute onset of dementia responded to a treatment with infliximab. In glucocorticoid-resistant patients, it is important to consider the introduction of infliximab to prevent irreversible brain dysfunction.
UR - http://www.scopus.com/inward/record.url?scp=85109092668&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109092668&partnerID=8YFLogxK
U2 - 10.1016/j.jneuroim.2021.577631
DO - 10.1016/j.jneuroim.2021.577631
M3 - Article
C2 - 34153801
AN - SCOPUS:85109092668
SN - 0165-5728
VL - 357
JO - Journal of Neuroimmunology
JF - Journal of Neuroimmunology
M1 - 577631
ER -